{
  "docId": "019de518-8187-71ee-8986-2e2b4f086024",
  "docSlug": "c86b127de51d9f444a871d8a6cb4bc21",
  "documentTitle": "Waldencast | Results Presentation Deck | 63 slides",
  "authorId": "waldencast",
  "authorName": "Waldencast",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 59,
  "pageCount": 63,
  "prevPage": 58,
  "nextPage": 60,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 48,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de518-8187-71ee-8986-2e2b4f086024/59",
  "deckHref": "/decks/019de518-8187-71ee-8986-2e2b4f086024",
  "deckJsonHref": "/decks/019de518-8187-71ee-8986-2e2b4f086024.json",
  "deckAnchorHref": "/decks/019de518-8187-71ee-8986-2e2b4f086024#slide-59",
  "components": [
    {
      "bbox": {
        "h": 0.046,
        "w": 0.909,
        "x": 0.06,
        "y": 0.928
      },
      "kind": "source-note",
      "text": "1 Includes mainly legal, advisory and consultant fees related to the financial restatement for FY 2022 and associated regulatory investigation. 2 Relates to the fair value of the related party liability for the unfavorable discount to the Obagi Medical China Business as part of the Business Combination. 3 Other non-recurring costs include the amortization of the fair value step-up as a result of the business combination, legal settlements, foreign currency transaction losses, the cost and gain of the recovery of inventory from the Vietnam distributor, and product discontinuation costs related to advanced purchases for the Vietnam distributor, and a one-time contract termination cost and lease impairment.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75d3986d-f0e1-4d6e-a3c6-63317ec30c0b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.649,
        "w": 0.65,
        "x": 0.178,
        "y": 0.18
      },
      "kind": "table",
      "text": "Three Months Ended June 30, 2024: Net Loss $(9,012), Depreciation and amortization 15,130, Interest expense, net 4,419, Income tax benefit (1,669), Stock-based compensation expense 3,468, Legal and advisory non-recurring costs(1) 2,515, Change in fair value of warrants and interest rate collar (8,572), Amortization of related party liability(2) (461), Other costs(3) 515, Adjusted EBITDA 6,333, Net Revenue $63,311, Net Loss % of Net Revenue (14.2)%, Adjusted EBITDA Margin 10.0%. Three Months Ended June 30, 2023: Net Loss $(23,511), Depreciation and amortization 14,634, Interest expense, net 5,132, Income tax benefit (2,061), Stock-based compensation expense 1,284, Legal and advisory non-recurring costs(1) 7,689, Change in fair value of warrants and interest rate collar (1,137), Amortization of related party liability(2) -, Other costs(3) 1,820, Adjusted EBITDA 3,850, Net Revenue $49,386, Net Loss % of Net Revenue (47.6)%, Adjusted EBITDA Margin 7.8%. Six months ended June 30, 2024: Net Loss $(12,906), Depreciation and amortization 30,014, Interest expense, net 8,711, Income tax benefit (2,353), Stock-based compensation expense 4,526, Legal and advisory non-recurring costs(1) 10,439, Change in fair value of warrants and interest rate collar (20,732), Amortization of related party liability(2) (778), Other costs(3) 763, Adjusted EBITDA 17,684, Net Revenue $131,582, Net Loss % of Net Revenue (9.8)%, Adjusted EBITDA Margin 13.4%. Six months ended June 30, 2023: Net Loss $(36,780), Depreciation and amortization 30,261, Interest expense, net 9,611, Income tax benefit (4,509), Stock-based compensation expense 5,476, Legal and advisory non-recurring costs(1) 10,624, Change in fair value of warrants and interest rate collar (1,467), Amortization of related party liability(2) (2,371), Other costs(3) 3,059, Adjusted EBITDA 13,904, Net Revenue $109,338, Net Loss % of Net Revenue (33.6)%, Adjusted EBITDA Margin 12.7%.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "770966e0-04f7-4aa2-ac2b-37e39222cab7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.419,
        "x": 0.059,
        "y": 0.08
      },
      "kind": "title",
      "text": "GROUP ADJUSTED EBITDA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6424464-b934-4c3e-a3ad-9d45fb6de690",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "ed9b7c30-49c4-4f11-a903-dfb79dd89b58",
      "evidence": "table/data: Three Months Ended June 30, 2024: Net Loss $(9,012), Depreciation and amortization 15,130, Interest expense, net 4,419, Income tax benefit (1,669), Stock-based compensation expense 3,468, Legal and advisory n",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 63,
      "from": 30,
      "beatId": "baa15d82-9759-465a-a993-c604af8f7bb2",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Financials",
      "beatSlug": "sequoia-pitch-financials",
      "evidence": "Slides 30-63 provide detailed financial information, including key figures and revenue buildup",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}